See more : Strategic Acquisitions, Inc. (STQN) Income Statement Analysis – Financial Results
Complete financial analysis of MoonLake Immunotherapeutics (MLTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MoonLake Immunotherapeutics, a leading company in the Biotechnology industry within the Healthcare sector.
- Lasertec Corporation (6920.T) Income Statement Analysis – Financial Results
- AgileThought, Inc. (AGILQ) Income Statement Analysis – Financial Results
- Target Group Inc. (CBDY) Income Statement Analysis – Financial Results
- Skyward Specialty Insurance Group, Inc. (SKWD) Income Statement Analysis – Financial Results
- Farmers Bankshares, Inc. (FBVA) Income Statement Analysis – Financial Results
MoonLake Immunotherapeutics (MLTX)
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 13.16K | 12.36K | 4.97K | 0.00 |
| Gross Profit | -13.16K | -12.36K | -4.97K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 31.80M | 42.05M | 35.52M | 0.00 |
| General & Administrative | 22.32M | 23.01M | 21.66M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 18.03M | 0.00 |
| SG&A | 22.32M | 23.01M | 18.05M | 105.76K |
| Other Expenses | 0.00 | 591.73K | 0.00 | 0.00 |
| Operating Expenses | 54.12M | 65.06M | 53.57M | 105.76K |
| Cost & Expenses | 54.12M | 65.06M | 53.58M | 105.76K |
| Interest Income | 0.00 | 0.00 | 0.00 | 14.92K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 13.16K | 12.36K | 4.97K | 206.30K |
| EBITDA | -54.11M | -65.05M | -53.63M | -90.84K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -54.12M | -65.06M | -53.58M | -105.76K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 10.14M | 591.73K | 10.65M | 14.92K |
| Income Before Tax | -43.98M | -64.47M | -53.64M | -90.84K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 94.39K | 36.37K | 4.76K | -206.30K |
| Net Income | -36.01M | -64.51M | -53.64M | -90.84K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.73 | -2.20 | -6.84 | -0.01 |
| EPS Diluted | -0.73 | -2.20 | -6.84 | -0.01 |
| Weighted Avg Shares Out | 49.12M | 29.36M | 7.84M | 14.81M |
| Weighted Avg Shares Out (Dil) | 49.12M | 29.36M | 7.84M | 14.81M |
Why MoonLake (MLTX) Might Surprise This Earnings Season
MoonLake Immunotherapeutics (MLTX) is on the Move, Here's Why the Trend Could be Sustainable
What Makes MoonLake Immunotherapeutics (MLTX) a New Buy Stock
Why MoonLake Immunotherapeutics Stock Shot Up 41.1% on Tuesday
Why MoonLake Immunotherapeutics Shares Are Surging Higher Today
Source: https://incomestatements.info
Category: Stock Reports